Key result
Larger waist circumference linked to ~5% higher predicted 10-year ASCVD risk in adults with HIV.
Why the study?
What is the prevalence and what are the modifiable clinical correlates of elevated predicted 10-year ASCVD risk among adults living with HIV on antiretroviral therapy in Zambia?
Cross-Sectional (n=130)
Single-blind (echocardiographers blinded to ASCVD risk)
No
What is the prevalence and what are the modifiable clinical correlates of elevated predicted 10-year ASCVD risk among adults living with HIV on antiretroviral therapy in Zambia?
Odds Ratio: 1.05 (95% CI 1–1.1)
p-value: p=0.038
Among virologically suppressed adults living with HIV in Zambia, 11.5% have elevated predicted 10-year ASCVD risk, which correlates most robustly with central adiposity (waist circumference) rather than inflammatory biomarkers.
No takes yet. Share an insight, caveat, or question.
Chaile et al. (2026) conducted a cross-sectional in HIV on stable antiretroviral therapy (n=130). Waist circumference (central adiposity) vs. Lower waist circumference was evaluated on Elevated predicted 10-year ASCVD risk (≥10% using ACC/AHA pooled cohort equations) (AOR 1.05, 95% CI 1.00–1.10, p=0.038). Waist circumference was independently associated with an elevated predicted 10-year ASCVD risk among adults living with HIV on antiretroviral therapy (AOR 1.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: